CARsgen Therapeutics Holdings Limited reported that its authorized share capital remained at 200.00 billion ordinary shares with a par value of USD 0.00000025 each, totaling USD 50,000. As of the close of February 2026, there were 570.31 million issued shares (excluding treasury shares) alongside 7.82 million treasury shares, resulting in a total of 578.13 million issued shares—unchanged from the prior month.

The company confirmed that its public float requirement of 25% remained fulfilled. Under the Post-IPO Share Option Scheme, 14.60 million share options were outstanding at the beginning of February. After 40,000 options lapsed, 14.56 million remained, and 27.66 million shares in total could be issued under the scheme. Furthermore, 2.32 million shares remained issuable under the 2019 Equity Incentive Plan.

No new shares were issued during the month, and no shares were transferred out of treasury. A total of 0.46 million shares had been repurchased previously but were not yet canceled as of the end of February 2026.